Kelsee (Dienogest, Ethinylestradiol | Lactose)

The ethinylestradiol component supplies estrogen, stabilising the endometrium, while dienogest provides progestogenic activity that suppresses the luteinising hormone surge, preventing ovulation. Together they also thicken cervical mucus and alter the uterine lining, creating conditions unsuitable for fertilisation and implantation.

The dosing regimen for Kelsee is determined by the prescribing healthcare professional. Typically, combined oral contraceptives are taken once daily for a 21‑day active phase followed by a hormone‑free interval, but the exact schedule should be confirmed with the prescriber.

Kelsee is contraindicated during pregnancy because it is intended to prevent conception. If pregnancy occurs, the product should be discontinued. Safety during breastfeeding is not established; clinicians usually advise against use while nursing and may recommend alternative contraception.

To order Kelsee, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and necessary import documentation.

Kelsee contains the progestogen dienogest, which has a higher anti‑androgenic profile than many older progestins, potentially offering better control of acne and menstrual symptoms. Its efficacy in preventing pregnancy is comparable to other combined oral contraceptives, while the side‑effect profile may differ slightly based on the progestin component.

Kelsee tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original blister pack, protect from moisture and direct sunlight, and store out of reach of children.

Kelsee is taken orally, usually once daily at the same time each day. The tablets are swallowed with water and are not to be chewed or crushed. Patients should follow the prescribed cycle, typically 21 active tablets followed by a hormone‑free interval.

The most serious risks include venous thromboembolism (deep‑vein thrombosis, pulmonary embolism), arterial thrombosis (stroke, myocardial infarction), severe hypertension, and rare hepatic tumors. Patients should be aware of symptoms such as sudden leg pain, chest pain, shortness of breath, severe headache, or visual changes and seek immediate medical attention.

Kelsee is contraindicated in women with a history of thromboembolic disorders, active liver disease, known or suspected breast cancer, uncontrolled hypertension, or those who are pregnant or breastfeeding. It should also be avoided by smokers over 35 years of age and individuals taking interacting medications that reduce contraceptive efficacy.